In summary, this study highlights the ‘BAX/BAK-like’ protein BOK as a prognostic marker in CRC, with increased BOK tumour levels indicating unfavourable clinical outcome in Stage II/III CRC patients. This evidence concerns the gene BAX and neoplasm.